Blueprint Medicines Co. (NASDAQ:BPMC) COO Sells 2,274 Shares

Blueprint Medicines Co. (NASDAQ:BPMC) COO Christina Rossi sold 2,274 shares of the stock in a transaction dated Monday, March 24th. The shares were sold at an average price of $95.02, for a total value of $216,075.48. Following the completion of the transaction, the chief operating officer now owns 69,266 shares in the company, valued at approximately $6,581,655.32. The trade was a 3.18 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Christina Rossi also recently made the following trade(s):

• On Tuesday, January 21st, Christina Rossi sold 2,274 shares of Blueprint Medicines stock. The shares were sold at an average price of $110.14, for a total transaction of $250,458.36.

Blueprint Medicines Price Performance

BPMC traded down $2.36 on Wednesday, hitting $90.72. 606,651 shares of the company were exchanged, compared to its average volume of 712,138. The business’s fifty day moving average is $99.12 and its 200 day moving average is $93.97. The firm has a market capitalization of $5.80 billion, a P/E ratio of -84.00 and a beta of 0.58. The company has a debt-to-equity ratio of 1.15, a quick ratio of 2.80 and a current ratio of 2.85. Blueprint Medicines Co. has a fifty-two week low of $80.68 and a fifty-two week high of $121.90.

Blueprint Medicines (NASDAQ:BPMC) last announced its quarterly earnings results on Thursday, February 20th. The biotechnology company reported ($0.79) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.68) by ($0.11). Blueprint Medicines had a negative net margin of 13.19% and a negative return on equity of 77.49%. As a group, sell-side analysts anticipate that Blueprint Medicines Co. will post -1.28 EPS for the current year.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on BPMC. Morgan Stanley assumed coverage on shares of Blueprint Medicines in a report on Thursday, March 20th. They issued an “equal weight” rating and a $100.00 target price for the company. HC Wainwright reiterated a “buy” rating and set a $135.00 target price on shares of Blueprint Medicines in a research report on Friday, February 14th. Wolfe Research initiated coverage on Blueprint Medicines in a research report on Tuesday, March 18th. They issued an “outperform” rating for the company. Needham & Company LLC reaffirmed a “buy” rating and set a $133.00 price target on shares of Blueprint Medicines in a research report on Thursday, February 13th. Finally, Jefferies Financial Group assumed coverage on Blueprint Medicines in a report on Monday, March 17th. They issued a “buy” rating and a $135.00 price objective for the company. Two equities research analysts have rated the stock with a sell rating, six have assigned a hold rating, fifteen have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $124.95.

Hedge Funds Weigh In On Blueprint Medicines

Hedge funds have recently bought and sold shares of the stock. California State Teachers Retirement System raised its stake in Blueprint Medicines by 4.9% in the 4th quarter. California State Teachers Retirement System now owns 59,259 shares of the biotechnology company’s stock valued at $5,169,000 after purchasing an additional 2,742 shares during the last quarter. Mackenzie Financial Corp raised its position in shares of Blueprint Medicines by 99.6% in the fourth quarter. Mackenzie Financial Corp now owns 14,177 shares of the biotechnology company’s stock valued at $1,237,000 after buying an additional 7,076 shares during the last quarter. GF Fund Management CO. LTD. purchased a new stake in shares of Blueprint Medicines in the fourth quarter valued at $116,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its holdings in Blueprint Medicines by 5.3% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 239,946 shares of the biotechnology company’s stock valued at $20,928,000 after buying an additional 12,035 shares during the period. Finally, Woodline Partners LP boosted its position in shares of Blueprint Medicines by 19.1% in the fourth quarter. Woodline Partners LP now owns 540,192 shares of the biotechnology company’s stock worth $47,116,000 after acquiring an additional 86,614 shares during the last quarter.

About Blueprint Medicines

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.